Convalescent plasma for COVID-19: Promising, not proven

Cleve Clin J Med. 2020 Nov 2;87(11):664-670. doi: 10.3949/ccjm.87a.ccc056.

Abstract

While promising, convalescent plasma remains experimental and is not proven effective for COVID-19. In addition, many questions remain regarding the accuracy and predictive value of antibody testing of donors and patients, optimal donor selection, optimal timing, and selection of patients most likely to benefit. Until these questions are answered, convalescent plasma should ideally be used in the context of well-designed clinical trials.

MeSH terms

  • Betacoronavirus* / immunology
  • Betacoronavirus* / isolation & purification
  • COVID-19
  • COVID-19 Serotherapy
  • COVID-19 Testing
  • Clinical Laboratory Techniques / methods*
  • Clinical Trials as Topic
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / genetics
  • Coronavirus Infections* / immunology
  • Coronavirus Infections* / therapy
  • Donor Selection
  • Humans
  • Immunization, Passive / adverse effects
  • Immunization, Passive / methods
  • Pandemics*
  • Patient Selection
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / genetics
  • Pneumonia, Viral* / immunology
  • Pneumonia, Viral* / therapy
  • Predictive Value of Tests
  • Reproducibility of Results
  • Risk Assessment
  • SARS-CoV-2
  • Time-to-Treatment*
  • Treatment Outcome